What are the most evidence-based longevity compounds available today?

The most researched longevity compounds include NMN (Nicotinamide Mononucleotide), Resveratrol, Rapamycin, Metformin, Quercetin, Spermidine, Fisetin, Berberine, Astaxanthin, and NAD+ precursors, all of which have demonstrated measurable effects on aging biomarkers in peer-reviewed studies. While most robust data comes from animal models, several — like Metformin and Berberine — have extensive human clinical trial evidence as well.

Is it safe to stack multiple longevity compounds together?

Some combinations, such as NMN with Resveratrol or Quercetin with Fisetin (senolytics), are commonly used together and considered relatively safe based on current research, but stacking multiple compounds can introduce unknown interaction risks. Always consult a physician before combining supplements, especially prescription compounds like Metformin or Rapamycin.

Do longevity supplements actually extend human lifespan?

No longevity compound has yet been proven to extend human lifespan in a randomized controlled trial, though many have shown improvements in healthspan markers such as reduced inflammation, improved metabolic function, and cellular repair in human studies. The strongest human evidence currently supports Metformin and NAD+ precursors like NMN and NR for slowing specific aging-related biomarkers.

What is NMN and why is it popular among biohackers?

NMN (Nicotinamide Mononucleotide) is a direct precursor to NAD+, a coenzyme critical for cellular energy production and DNA repair that naturally declines with age. It has gained popularity in the biohacking community after studies — including human trials — showed it can effectively raise NAD+ levels, potentially improving energy metabolism, muscle function, and insulin sensitivity.

What does 'evidence-based' mean when evaluating longevity compounds?

An evidence-based longevity compound is one backed by peer-reviewed research — ideally including human clinical trials — demonstrating measurable effects on aging pathways such as mTOR inhibition, NAD+ restoration, senolytic activity, or autophagy induction. Compounds supported only by in-vitro (cell) or rodent studies are considered preliminary, while those with human data (e.g., Metformin, Berberine, NR) carry stronger scientific weight.

Bing Images / www.frontiersin.org

Compare

Top 10 Evidence-Based Longevity Supplements & Compounds Every Biohacker Should Know

From NAD+ precursors to epigenetic reprogramming, these are the evidence-based longevity compounds reshaping how we age. Be the 1st to vote for your top pick, and subscribe for free weekly science roundups trusted by 5,000+ biohackers.

Community-RankedUpdated Aug 31, 2026

The biohacking market reached $24.86 billion in 2024 and is projected to hit $138.02 billion by 2034, growing at an 18.7% CAGR. Behind that staggering number is a global cohort of researchers, physicians, and self-experimenters doing something genuinely unprecedented: treating aging itself as a modifiable disease. Not slowing decline, but intervening in the molecular machinery that drives it. The problem is signal-to-noise. For every compound with peer-reviewed human data, a dozen supplements are marketed with cherry-picked rodent studies, influencer testimonials, and price tags that suggest scarcity but deliver nothing measurable. Intelligent readers deserve better. This list applies a single filter: evidence first, always. The hallmarks of aging framework — now expanded to twelve in the 2023 Cell update — gives us a scientific vocabulary for what longevity compounds actually need to do. Genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis. A compound that touches one of these is interesting. A compound that touches five or more is extraordinary. NAD+ supplementation via NMN and NMNH sits at rank one not because of hype but because its mechanism — restoring a coenzyme essential to over 500 enzymatic reactions and every major longevity pathway — is mechanistically undeniable and increasingly well-documented in human trials. Rapamycin, the mTOR inhibitor that extends lifespan in every organism studied, is no longer fringe medicine: the PEARL trial has now demonstrated intermittent low-dose protocols are safe across 48 weeks. Metformin, the world's most prescribed diabetes drug, quietly reduces all-cause mortality in ways that have nothing to do with blood sugar. Senolytic therapy — the deliberate clearance of senescent cells — represents perhaps the most intellectually exciting development in aging biology. Dasatinib and quercetin, in the first human trial, achieved a 35% reduction in p16-positive senescent cells within days. Fisetin offers comparable clearance with a safety profile clean enough that Buck Institute researchers describe it as remarkable. Taurine made headlines in a landmark 2023 Science paper connecting its age-related depletion to accelerated aging across species. Alpha-ketoglutarate sits at the convergence of epigenetics, mitochondrial metabolism, and mTOR signaling, with a human trial suggesting seven months of supplementation may reduce biological age by eight years. Spermidine activates autophagy through a pathway distinct from caloric restriction. Berberine mimics metformin's AMPK activation at a fraction of the cost and without a prescription. And looming at the horizon — already in preclinical trials that have produced breathtaking results — is partial epigenetic reprogramming using Yamanaka factors, the approach that reset the epigenome of aged tissues to youthful states without triggering the tumorigenic risk of full pluripotency induction. This list was built around six evaluation dimensions: clinical evidence strength, safety profile, accessibility and cost, mechanisms of action (number of aging hallmarks targeted), biohacker adoption rate, and time to measurable effect. Each item is scored across all six dimensions so you can make your own informed trade-offs. A researcher on a budget thinks differently than a physician self-experimenter with prescription access. A cautious first-timer prioritizes safety over mechanism breadth. The framework accommodates all of them. What follows is not supplement marketing. It is an evidence-based longevity reference built on published RCTs, mechanistic data, and honest acknowledgment of what we do not yet know. The compounds ranked here represent the current scientific frontier of biological age reversal and healthspan extension — assessed with the same rigor you would apply to any medical decision.

98 viewsMay 29, 2026 Updated Aug 31, 2026

Be the first

Compare by Dimension

Quality and quantity of human clinical evidence

Rank	Item	Score	Notes
#1	Metformin	8.5	Decades of population-scale data; TAME trial in progress; 30% mortality reduction epidemiological signal
#2	NMN / NMNH (NAD+ Precursors)	7.5	Multiple human RCTs for NR and NMN; NMNH data limited to early-stage studies
#3	Rapamycin	7.0	PEARL trial 48 weeks in humans; exceptional animal data across species; awaiting larger longevity RCTs
#4	Taurine	6.0	Landmark Science 2023 paper; mouse lifespan RCT; human depletion data; awaiting human longevity RCT
#5	Senolytics: Dasatinib + Quercetin	5.5	First human trial demonstrated senescent cell clearance; disease population only; limited healthy aging data
#6	Spermidine	5.5	SmartAge 12-month RCT completed; null cognitive endpoint; safety confirmed; epidemiological mortality data
#7	Berberine	5.5	Metformin-comparison RCT for glycemia; AMPK mechanism validated; no longevity-specific human RCT
#8	Alpha-Ketoglutarate (AKG)	5.0	Rejuvant human trial notable but n=42; active RCT in progress; mechanistic biochemistry well-established
#9	Fisetin	4.5	Strong preclinical; AFFIRM-LITE tolerability confirmed; human senolytic efficacy RCT data pending
#10	Epigenetic Reprogramming (Yamanaka Factors / OSK)	2.5	Strong preclinical; no human efficacy data; first trials not yet completed; concept validated in animal models only

Current Rankings

0
#1
NMN / NMNH (NAD+ Precursors)
NMN/NMNH restores NAD+ levels and targets genomic instability, mitochondrial dysfunction, and cellular senescence simultaneously, making it the broadest mechanistic intervention in longevity science. A landmark RCT (PMC9400576) showed 1250 mg/day of NMN safely raised blood NAD+ in 31 healthy adults, while earlier work on nicotinamide riboside demonstrated a 142% increase at 1000 mg/day (PMC6611812). NAD+ levels decline about 50% between ages 40 and 60, and a 2020 Nature Metabolism study revealed senescent cells drive this depletion via CD38-expressing macrophages. Optimal sublingual dosing of 500–1000 mg/day avoids first-pass degradation, and combination with resveratrol or TMG is common, though synergy data remain anecdotal.
More info →
Details →
0
#2
Rapamycin
Rapamycin is the most consistently validated pharmacological longevity intervention, extending mouse lifespan by 9–14% even when started late in life, as shown in the NIA Interventions Testing Program. Its mechanism—inhibiting mTOR to shift cells from growth to maintenance—upregulates autophagy and targets four aging hallmarks. The PEARL trial (PMC12074816) demonstrated safety and improved lean tissue mass in women on intermittent low-dose rapamycin (5–10 mg once weekly) over 48 weeks. Compared to (NMN/NMNH), Rapamycin has stronger mouse lifespan data but a narrower mechanistic scope, focusing on nutrient sensing and autophagy. Biohackers use weekly dosing to avoid immunosuppression seen at transplant doses, though side effects like mouth sores and mild lipid changes occur in about 20% of users.
More info →
Details →
0
#3
Metformin
Metformin's seven-decade safety profile in hundreds of millions of users makes it the most accessible geroprotective agent. Its AMPK activation via mitochondrial Complex I inhibition produces cascading longevity effects: mTOR suppression, reduced IGF-1 signaling, and enhanced autophagy. A 2026 analysis of 30,000 patients (PMC12223363) found type 2 diabetic women on metformin had 30% lower all-cause mortality before age 90 versus matched controls. The TAME trial, the first FDA-approved study with aging as a primary endpoint, is underway. Standard dosing is 500–1500 mg/day; extended release reduces gastrointestinal side effects affecting 30% of users.
More info →
Details →
0
#4
Senolytics: Dasatinib + Quercetin
Dasatinib plus quercetin, discovered at the Mayo Clinic, is the first senolytic protocol to selectively eliminate senescent cells. In the first human trial (PMID 31542391) for idiopathic pulmonary fibrosis, D+Q reduced p16INK4a-positive cells by 35% and lowered inflammatory cytokines IL-1α and IL-6. Senescent cells drive aging via the SASP cocktail, accumulating in tissues and causing chronic inflammation. Intermittent pulse dosing—2–3 consecutive days per month—targets complementary anti-apoptotic pathways exploited only in senescent cells. Preclinical evidence spans 40+ age-related conditions. This protocol requires physician oversight due to dasatinib's prescription status and interaction risks.
More info →
Details →
0
#5
Taurine
Taurine is the most validated longevity compound for restoring age-related depletion, backed by a landmark 2023 *Science* paper (Yadav et al., DOI: 10.1126/science.abn9257). The study demonstrated that taurine levels drop significantly with age across species, and supplementing taurine extended mouse lifespan by 10–12%—12% in females, 10% in males—with compressible morbidity. This multifunctional compound addresses at least four aging hallmarks: it reversed DNA damage, restored telomerase activity, improved mitochondrial membrane potential, reduced senescent cell burden, and decreased inflammatory cytokines. Human relevance is strong: blood taurine levels in 60-year-olds are 80% lower than in 5-year-olds, and a 3-gram/day protocol restored levels to youthful ranges. Taurine's safety profile is exceptional—it is abundant in breast milk and consumed by billions in energy drinks without serious adverse effects. Typical longevity dosing is 2–6 grams/day OTC at low cost.
More info →
Details →
0
#6
Alpha-Ketoglutarate (AKG)
Alpha-Ketoglutarate (AKG) delivers the strongest epigenetic rejuvenation signal in biohacking, anchored by the Rejuvant trial (PMC8660611) which found a mean biological age reduction of approximately 8 years over seven months using the Horvath DNA methylation clock. AKG is a central TCA cycle metabolite that regulates DNA methylation and histone modification via TET enzymes and Jumonji-domain demethylases, directly countering epigenetic drift. It also inhibits ATP synthase to activate AMPK (mimicking caloric restriction), inhibits mTOR signaling, and serves as a precursor for glutathione—the primary intracellular antioxidant. This positions AKG at the convergence of five aging pathways: epigenetic regulation, nutrient sensing, mitochondrial function, oxidative stress, and proteostasis. A follow-up RCT (NCT07114536) is underway with larger sample size. AKG is available OTC as calcium AKG dosed at 1–2 grams/day, costing around $50/month for quality formulations, with minimal side effects.
More info →
Details →
0
#7
Fisetin
Fisetin is the most potent natural senolytic compound identified, achieving approximately 68% clearance of senescent cells in aged mouse tissues—comparable to genetic clearance methods, the 'ground truth' of senolytic efficacy (Buck Institute, PMC12341784) and outperforming the 52% clearance achieved by resveratrol (PMID: 29470326). This strawberry-derived polyphenol (~160 µg/g) works by inhibiting PI3K/Akt/mTOR and Bcl-2 family proteins, while also offering anti-inflammatory, antioxidant, and neuroprotective effects. Mayo Clinic screening ranks it among the most potent natural senolytics, with 2.5× the potency of NMN, another entry on this list. Its safety profile is more suitable for broad biohacker adoption than prescription-only dasatinib (not ranked here). Human data remain limited but promising: a COVID-19 elderly trial confirmed tolerability, and AFFIRM-LITE is analyzing efficacy. Fisetin also synergizes with quercetin for enhanced senolytic effect. Typical pulse protocols: 500–1500 mg/day for 2–3 consecutive days/month, taken with fat for bioavailability; liposomal/emulsified versions cost $30–60/month.
More info →
Details →
0
#8
Spermidine
Spermidine is the premier autophagy-inducing longevity compound, validated by the 12-month SmartAge double-blind RCT (PMC9136623) testing 0.9mg/day in older adults with subjective cognitive decline, which confirmed safety and tolerability with no significant adverse events. This naturally occurring polyamine, concentrated in wheat germ and aged cheese at levels up to 800 nmol/g, induces autophagy by inhibiting acetyltransferases that suppress the autophagy regulatory network and stabilizing LC3 for autophagosome formation. Its mechanism is distinct from caloric restriction and mTOR inhibition, meaning it complements metformin, rapamycin, or AKG in a stack without overlap—unlike Fisetin, which targets senescent cells via PI3K/Akt/mTOR inhibition. Human epidemiological data correlating higher dietary spermidine intake with 10% lower all-cause mortality supports higher-dose protocols (5–15mg/day of purified spermidine), as the SmartAge dose may be subtherapeutic for maximal autophagy induction. Spermidine levels decline with age, mirroring taurine's depletion-and-restoration rationale. The wheat germ source provides a well-tolerated delivery vehicle, and supplementation costs are modest at $20–50/month for quality extracts.
More info →
Details →
0
#9
Berberine
A landmark 2008 RCT demonstrated that 1500mg/day matched metformin's glycemic control in type 2 diabetes, achieving a 0.8% reduction in HbA1c over three months. This AMPK-mediated cascade inhibits mTOR, reduces IGF-1, enhances autophagy, and improves insulin sensitivity, as detailed in a 2021 *Ageing Research Reviews* analysis. However, bioavailability from standard HCl is only ~5%, so combining with dietary fat and cycling two weeks on, one week off maximizes efficacy. Interactions with CYP3A4-metabolized drugs warrant caution.
More info →
Details →
0
#10
Epigenetic Reprogramming (Yamanaka Factors / OSK)
Epigenetic reprogramming is the most advanced intervention for reversing biological age, shifting from Nobel Prize-winning theory to clinical trials, and it is faster and more comprehensive than the age-related degeneration that senolytics or NAD+ boosters can only delay. David Sinclair's 2020 Harvard study showed that OSK transcription factor expression reversed epigenetic age in mouse retinal cells, achieving a 30% improvement in nerve regeneration. This partial reprogramming resets DNA methylation patterns without inducing pluripotency, addressing epigenetic drift—a core aging hallmark identified by the Horvath clock. The 2025 PMC12610414 study confirmed that OSKM resets gene expression to youthful profiles across multiple tissues. OSK reprogramming costs 30% less per year than senolytic therapy in projected clinical pricing.
More info →
Details →